Abstract
The in vitro activity of contezolid (MRX-I) against clinical isolates of Mycobacterium tuberculosis was evaluated using a microtiter broth dilution assay. MRX-I was as effective as linezolid (LZD) in vitro MRX-I and LZD were subsequently studied in BALB/c mice infected intranasally with M. tuberculosis Erdman. MRX-I and LZD at 100 mg/kg significantly reduced the bacterial load in lungs compared to the untreated early and late controls.
Keywords:
Mycobacterium tuberculosis; in vitro; mouse model; oxazolidinones.
Copyright © 2018 American Society for Microbiology.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antitubercular Agents / pharmacology*
-
Bacterial Load / drug effects
-
Disease Models, Animal
-
Drug Administration Schedule
-
Female
-
Humans
-
Isoniazid / pharmacology
-
Linezolid / pharmacology
-
Lung / drug effects
-
Lung / microbiology
-
Mice
-
Mice, Inbred BALB C
-
Microbial Sensitivity Tests
-
Mycobacterium tuberculosis / drug effects*
-
Mycobacterium tuberculosis / growth & development
-
Mycobacterium tuberculosis / isolation & purification
-
Oxazolidinones / pharmacology*
-
Pyridones / pharmacology*
-
Tetrazoles / pharmacology
-
Tuberculosis, Multidrug-Resistant / drug therapy*
-
Tuberculosis, Multidrug-Resistant / microbiology
Substances
-
Antitubercular Agents
-
Oxazolidinones
-
PNU-100480
-
Pyridones
-
Tetrazoles
-
tedizolid
-
contezolid
-
Linezolid
-
Isoniazid